TORONTO, June 12, 2020 /CNW/ - Khiron Life Sciences
Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX:
KHRNF), (Frankfurt: A2JMZC), a
vertically integrated cannabis leader with core operations in
Latin America and Europe, announces today the appointment of
Chris Naprawa as Director and
Chairman of the Board. In transitioning from his current role as
President, Chris will continue to guide the Company and Board as
Khiron continues its commercialization phase of its medical
cannabis business strategy in Latin
America and globally. The Company further announces that
Michael Beck has resigned from the
Board, including as member of the Audit and Compensation
Committees, effective immediately.
"I congratulate Chris on this appointment which comes at a
dynamic time for the Company. Today we are a recognized cannabis
leader in Latin America,
generating revenue and market share as the first and only company
authorized for low- and high-THC sales in Colombia, and with expanded sales activity in
Latin America, Europe and beyond. In his role as President,
Chris has played an integral part in these developments and in
increasing investor understanding of our business. As Chairman,
Chris will provide tremendous support and guidance to ensure our
focus on a continued and sustainable global growth," comments
Alvaro Torres, Khiron CEO, Director
and Co-Founder.
"On behalf of the Board I would also like to thank Michael for
his many contributions to Khiron after joining the Company's Board
a year ago. Since then, the Company has achieved many consequential
milestones regarding its international growth and has established
itself as a leader in the medical cannabis industry within
Latin America. On a personal note,
I am very grateful to Mike for his support and care of the health
and safety of our employees during the COVID-19 pandemic. We wish
him the best in his future endeavors," continued Alvaro Torres.
"When I first arrived at Khiron I was inspired by the vision of
Alvaro and the team, and the opportunity ahead. To now see our
first patients being helped by the medical cannabis products that
Khiron produces is humbling, and I look forward to seeing many more
in the coming years. In the last two years we have completed two
acquisitions and four financings and are one of the few cannabis
companies with a solid capital structure, as Khiron commercializes
product lines in several different markets. It has been a great
privilege to serve as President of this company, and work with this
incredible team of professionals, and I am excited to continue this
work in the new role," comments Chris
Naprawa, Khiron Board Chair.
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. is the dominant integrated medical
cannabis company in Latin America.
Khiron has core operations in Latin
America, along with activity in North America and Europe, and is licensed in Colombia for the cultivation, production,
domestic distribution, and international export of both
tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis.
The Company delivers best in class regulatory compliance, is fully
authorized to manufacture and fill prescriptions for high- and
low-THC medical cannabis in Colombia and has the first approved line of
CBD cosmetic products on shelf in Colombia, and available in
the United States and the
United Kingdom.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. The Company is led by Co-founder
and Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
Visit Khiron online at www.khiron.ca and on Instagram
@khironlife
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment analyses,
expectations or statements made by third-parties in respect of
Khiron, its securities, or financial or operating results (as
applicable). Although Khiron believes that the expectations
reflected in forward-looking statements in this press release are
reasonable, such forward-looking statement has been based on
expectations, factors and assumptions concerning future events
which may prove to be inaccurate and are subject to numerous risks
and uncertainties, certain of which are beyond Khiron's control,
including the risk factors discussed in Khiron's Annual Information
Form which is available on Khiron's SEDAR profile
at www.sedar.com. The forward-looking information contained in
this press release is expressly qualified by this cautionary
statement and are made as of the date hereof. Khiron disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise.
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-appoints-chris-naprawa-to-director-and-chairman-of-the-board-301075263.html
SOURCE Khiron Life Sciences Corp.